Our story

Ziphius Vaccines is named after the rare dolphin Ziphius cavirostris. This dolphin is most known for undertaking the deepest and longest dives recorded.

Ziphius Vaccines is a biopharmaceutical company, dedicated to develop saRNA vaccines and therapeutics. Ziphius focuses on both vaccines for infectious diseases and gene supplementation therapies for rare genetic disorders.

Since our founding in 2019, Ziphius has worked to develop and validate its self-amplifying RNA and LNP platforms. Currently, these platforms are being used to rapidly expand our pipeline and move forward multiple preclinical development programs towards the clinic.

Executive Committee

Chris Cardon

Chris Cardon

on behalf of Chimexport BV
Chief Executive Officer (CEO) & Founder
Mathieu Ghadanfar

Mathieu Ghadanfar, MD, FESC, FAHA

on behalf of M-Ghadanfar Consulting (Life sciences)
Chief Medical Officer (CMO)
Tom Almey

Tom Almey

on behalf of Almey-De Groote BV
Chief Operating Officer (COO)
Olivier Lemaire

Olivier Lemaire

on behalf of OLEM srl
General Counsel - Compliance Officer
Leonie wyffels

Leonie wyffels

on behalf of LIEASK BV
R&D Director
François Boitquin

François Boitquin

on behalf of Helidyn srl
Business Development

Board of directors

Board of directors
Chris Cardon

Chris Cardon

on behalf of Chimexport BV
Chief Executive Officer (CEO) & Founder

Annie Vereecken

on behalf of Heran BV
Non-Executive Director

Griet Nuytinck

on behalf of Post Verba Verbera NV
Non-Executive Director
Olivier Lemaire

Olivier Lemaire

on behalf of OLEM srl
General Counsel - Compliance Officer